OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of
calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact
parathyroid hormone levels in patients with tumoral calcinosis.
II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine
whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.
IV. Determine how repetitive calcitonin administration alters the biochemical markers of
bone metabolism in osteopenic patients with tumoral calcinosis.
PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of salmon calcitonin
every 3 weeks. Ondansetron premedication and intravenous hydration are also administered.
Patients are followed for disease progression and tumor recurrence.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Histologically confirmed tumoral calcinosis --Prior/Concurrent
Therapy-- Prior surgical resection of calcinotic lesion required